Halaven (eribulin mesylate)

P1/2, N=180, Not yet recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd

P2, N=180, Recruiting, Seoul National University Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Feb 2024 --> Dec 2026

The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.

P3, N=732, Active, not recruiting, AstraZeneca | Trial completion date: Aug 2025 --> Dec 2025

Notably, B. fragilis NCTC 9343 supernatant induced dose-dependent lactate dehydrogenase (LDH) release from the MCF-7 (HR-positive/HER2-negative) BC cell line. These findings suggest that specific gut and oral microbiota may modulate the effectiveness of combinatory anti-BC therapies, potentially through the action of microbial metabolites.

P1/2, N=28, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | N=106 --> 28

P=N/A, N=246, Not yet recruiting, Sun Yat-sen Memorial Hospital Sun Yat-sen University; Sun Yat-sen Memorial Hospital Sun Yat-sen University

The crucial event in pericyte phenotype switching was RhoA kinase activation, which distinguished CA-4 and eribulin effects from other anti-mitotic drugs such as paclitaxel and vinorelbine. Moreover, a contractile pericyte signature was associated with overall better survival outcome in two independent breast cancer cohorts. This underscores the potential of re-purposing specific anti-cancer drugs to enable synergistic complementation with emerging immunotherapies.

P3, N=246, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

P=N/A, N=66, Not yet recruiting, Fudan University

This multicentric, retrospective study highlights eribulin as a potential second-line therapy for MBC with a median response duration of 25 weeks after 6 infusions. The safety and efficacy profiles align with previous studies, supporting its role as a viable treatment option. Notably, the response and PFS were independent of hepatic metastasis, suggesting benefit across various MBC subtypes, including those with liver involvement. However, the retrospective design warrants cautious interpretation, and further prospective studies are needed to confirm these findings and optimize eribulin's use, potentially through molecular profiling for personalized treatment strategies.

In this case report, we describe the case of a highly pretreated patient with HER-2 positive metastatic breast cancer.

P2, N=90, Not yet recruiting, Delcath Systems Inc.

P3, N=404, Recruiting, BriaCell Therapeutics Corporation | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jan 2026

Preclinical studies have also suggested potential synergy with doxorubicin and eribulin, although these findings have yet to be validated in randomised clinical trials. Ongoing studies, such as the SeliSarc trial (NCT04595994) evaluating selinexor in combination with gemcitabine and the NRSTS2021 trial (NCT06239272) evaluating selinexor in paediatric soft tissue sarcoma, aim to further define its role. The results of these studies will be critical in determining whether selinexor can be incorporated into standard sarcoma treatment.

Eribulin demonstrates potent anti-glioma effects through apoptosis, mitochondrial dysfunction, and cell cycle disruption. These findings support its potential as a therapeutic option for glioblastoma treatment, warranting further investigation into its mechanisms and clinical applicability.

P1, N=42, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting

As a secondary in cellulo bioactivity screening, MDA-MB-231 genomically unstable aneuploid breast cancer cells were exposed to each compound in the absence and presence of 10 nM paclitaxel or 1 nM eribulin, the likely clinically relevant doses of these drugs in these cells. Two of the five compounds, which share a common 2-(trifluoromethyl)quinazolin-4-amine chemical structure, induced elevated levels of cell death in combination with paclitaxel, as observed by fluorescence-activated cell sorting (FACS). These two compounds will now serve as a starting point for further optimization and target validation experiments and for additional in silico screens in search of other chemically related small molecules that display more potent but specific anti-cancer cell effects.

P3, N=27, Active, not recruiting, Spanish Breast Cancer Research Group | Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025

Nomograms incorporating peripheral blood parameters may improve the accuracy of predicting OS and PFS in patients treated with eribulin. Our prediction model may help decision-making for breast cancer patients who are considering eribulin treatment.

This study highlights current chemotherapy practices for HR+/HER2- mBC in Japan, where treatment patterns largely align with clinical guidelines but vary according to patient characteristics. Notably, the TTNTD shortens with successive treatments, and medical costs increase, intensifying the financial burden on patients. These findings indicate unmet needs for improved treatment options that enhance outcomes and reduce patient burden in advanced therapy lines.

The patient was started on atezolizumab+nab-paclitaxel(PTX)therapy, but progression disease(PD)was observed without obvious effect. Pembrolizumab+carboplatin+gemcitabine was started as second-line therapy, and the tumor achieved partial response(PR)but developed PD within 6 months. After that, she was administrated olaparib, but PD was observed, and after the therapy with PTX+bevacizumab, she is now treated with eribulin.

P1, N=42, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

P2, N=30, Recruiting, Australia New Zealand Gynaecological Oncology Group | Trial primary completion date: Dec 2024 --> Mar 2025

P3, N=302, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2025

P2, N=78, Sichuan Cancer Hospital; Sichuan Cancer Hospital

P2, N=1460, Active, not recruiting, UNICANCER | Trial completion date: Dec 2024 --> Dec 2025

Evidence was reviewed from controlled clinical trials in which eribulin, vinorelbine, capecitabine, gemcitabine, gemcitabine plus carboplatin, fam-trastuzumab-deruxtecan, sacituzumab govitecan, olaparib, and talazoparib were used in the second-line treatment for metastatic breast cancer, either as study drugs or as comparators. Exploratory data for fam-trastuzumab-deruxtecan suggest a survival benefit in human epidermal growth factor receptor 2-low, hormone-receptor-negative patients, but further solid evidence is required. Other chemotherapies with lower European Society for Medical Oncology-Magnitude of Clinical Benefit Scale scores may continue to be useful in highly selected patients.

The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.

The patient received doxorubicin-based systemic chemotherapy as first-line therapy, which resulted in stable disease. After disease progression, the patient received eribulin monotherapy, which resulted in stable disease for 15 months...Therefore, the patient was started on trabectedin monotherapy during 16 months of stable disease, and thereafter received pazopanib after they presented with progressive disease on prior trabectedin monotherapy. It is likely that there are more patients with undiagnosed EWSR1::NFATC2 sarcoma. To make a definitive diagnosis, a thorough investigation should be performed.

P2, N=14, Recruiting, MedSIR | N=28 --> 14

P1/2, N=106, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P=N/A, N=80, Recruiting, Hunan Cancer Hospital

P3, N=504, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd

P2, N=40, Not yet recruiting, Fudan University

P3, N=254, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial completion date: Dec 2024 --> Mar 2025

We demonstrate in our exploratory study that biomarkers involved in the process of EMT could have a prognostic impact in a cohort of patients with BC uniformly treated and with long-term follow-up. Genes known to be involved in EMT were associated with improved eribulin efficacy, while suggesting a poorer outcome with CDK4/6i.

Hormonal or endocrine therapy includes selective estrogen receptor modulators (SERMs) such as raloxifene, tamoxifen and toremifene, selective estrogen-receptor degraders (SERDs) including elacestrant and fulvestrant, and aromatase inhibitors such as anastrozole, letrozole, and exemestane...These agents include taxanes (docetaxel, nab-paclitaxel, and paclitaxel), anthracyclines (doxorubicin, epirubicin), anti-metabolites (capecitabine, gemcitabine, fluorouracil, methotrexate), alkylating agents (carboplatin, cisplatin, and cyclophosphamide), and drugs that target microtubules (eribulin, ixabepilone, ado-trastuzumab emtansine). Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile.

P2, N=57, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Aug 2025 --> Jul 2024

P3, N=168, Recruiting, Shanghai Yizhong Pharmaceutical Co., Ltd. | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025